Reading the tape
NASDAQ: IVVD
Invivyd, Inc.
Healthcare · Biotechnology
Market Cap
$193.12M
52w High
$3.07
52w Low
$0.48
P/E
-4.77
Volume
201.08K
Outstanding Shares
132.73M
Price vs Fundamentals
Why The Stock Is Moving
Fundamentals are supporting the moveModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 155.47%Revenue (TTM): 110.47%FCF (TTM): 65.84%
What changed
The stock rose 155.47% over the last year. Revenue grew 110.47% over the trailing twelve months. Operating margin moved from -696.8% to -103.99%. Free cash flow grew 65.84% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum. The operating data is doing enough work that the move does not need an overvaluation story to explain it.
What would invalidate this read
Operating margin is at -103.99%. Revenue grew 110.47% — this thesis depends on that trajectory holding. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
CEOWilliam E. Duke Jr.
SectorHealthcare
IndustryBiotechnology
Employees99
IPO dateAug 6, 2021
Valuation
Forward P/E—
EV/EBITDA-3.76
Enterprise value$201.17M
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth24.51%
Gross margin92.99%▼0.68%vs FY2024
Operating margin-103.99%▲85.08%vs FY2024
ROE-21.73%▲91.36%vs FY2024
Analyst consensus
RatingBuy
Target price$9.50▲552.92%
4
Buy
3
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$0.08 · Revenue est $18.04M
View